Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.

Trial Details

NCT ID
NCT06437977
Phase
PHASE3
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SBRT
  • Toripalimab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged 18 -75 years, regardless of gender；
  • ECOG score 0-1;
  • Treatment-naive, histologically confirmed resectable, stage II, IIIA, IIIB (N2) (AJCC staging system, version 8) NSCLC ;
  • Measurable lesions based on the response evaluation criteria in solid tumors version 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →